# Celebrating our Kingscrowd 4.8/5 rating! 🌟 | Imago Rehab

- Canonical URL: https://wefunder.com/feed/1179992
- Entity ID: wefunder:feed_item:1179992
- Published at: 2026-11-19 16:00:00 UTC
- Updated at: 2026-11-19 16:07:35 UTC

## Author
Sharon Samjitsingh

## Subject
Imago Rehab

## Content
Kingscrowd, a leading research and analytics platform for online private market investing, just rated our round 4.8 out of a possible 5! Not only did we get a near-perfect score, Teddy Lyons, Senior Investment Associate at Kingscrowd, said this in the report:“Sharon is one of the most impressive founders I've ever met. I have no doubt she will continue to grow HCO into a long-term winner.”Our 4.8-star rating is well above the 3-star median rating for comparable growth-stage deals. Even more interesting, Kingscrowd's latest data shows that across Reg CF, higher-rated companies saw faster valuation growth when they raised again, and among companies that went public, they also saw stronger share-price increases. You can read the full analyst report on Kingscrowd’s site here. It’s behind a paywall, so we’ve pulled out some of the key highlights:Extensive team experience: Jared’s 25+ years of engineering and manufacturing background, Kristin’s 18 years in stroke therapy plus Harvard research, and my track record commercializing new technology, as well as my lived experience with asthma.Continuous monitoring: Our wearable ADAMM listens to the body’s signals continuously, and our purpose-built AI agents decode those signals to detect changes from each member’s own baseline.Market: Kingscrowd placed us in the $7.94B U.S. remote patient monitoring market growing 19.1% a year. While our position in this fast-growing market yielded a strong 4.4 / 5 score in the Market category, we believe our actual addressable market is much larger since our at-home clinical interventions go beyond monitoring, and ours is a platform technology. And our position in Physical AI for healthcare, owning the full stack from hardware through data, programs and outcomes is game-changing.Results: Revenue grew 17x in our last fiscal year, and HCO Neuro revenue is up 7.5x since we acquired Imago Rehab last September. Of the HCO Respiratory members who had attacks every month before joining, two in three report no attacks within six months. We now hold 41 patents granted and pending.I’m delighted with this rating, although I am not surprised by it. I’ve long known that we have differentiated technology and a strong team, both on the development side and on the member side. And our traction speaks for itself.This strong analyst rating also aligns with due diligence from top VCs. Every early bird investor in this round is investing at the same terms as Safar Partners, a $1.2B VC fund that invested $1.5M in the current round, along with Cranberry Capital, and many existing investors. Invest or increase your investment while early bird terms are still available: wefunder.com/hco/invest Sharon SamjitsinghCEO and Co-Founder, Health Care Originals